Neximmune Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Neximmune Inc in the second quarter 2024?
Neximmune Inc recorded a cumulative net loss of $-21 million during 12 months ending in the second quarter 2024, resulting in a negative return on equity (ROE) of -542.45%.

Within the Major Pharmaceutical Preparations industry 364 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2024 from 3019 to 3782.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2024) II. Quarter	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter
Y / Y Equity Change	-95.9 %	-88.37 %	-89.13 %	-82.7 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-21	-26	-32	-44	-49
Return On Equity (TTM)	-542.45 %	-328.24 %	-247.17 %	-216.32 %	-161.71 %
NEXI's Total Ranking	# 3782	# 3019	# 3042	# 3494	# 3806
Equity (TTM) in Millions	1	3	4	8	17
Seq. Equity Change	-74.61 %	-21.86 %	-57.48 %	-51.45 %	-27.89 %
Seq. Net Income Change	-	-	-	-	-

Back to NEXI Management Effectiveness >> NEXI's 5 Years Annual ROE >> Compare NEXI ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 365
Sector	# 772
Overall	# 3782

Return On Equity Statistics
High	Average	Low
-49.51 %	-186.15 %	-542.45 %
(Dec 31 2021)		(Jun 30 2024)

News about Neximmune Inc Return on Equity ROE

Navigating a Divergent Path Nvidias Rise and NexImmunes Struggles in the Stock Market

The financial markets are often a stage where contrasting fortunes play out in real time, painting a picture of industry trends and investor sentiment. This past month has been particularly telling, exemplified by the stark contrast between two companies: Nvidia and NexImmune. Nvidia: The AI Titan On July 29, 2024, Nvidia (NASDAQ: NVDA), the frontline warrior in the artificial intelligence sector, once again captured investor attention. The stock has been a runaway success, skyrocketing over the past eighteen months. It appears that not just market analysts, but also influential figures such as Elon Musk have weighed in on the matter. Musk’s insights into Nvidia’s potential underscore the company s status as a key player in AI technology, which has driven much of its stock appreciation. Investors are acutely aware that companies harnessing AI capabilities stand to flourish, as the demand for AI applications continues to surge across multiple industries.

NEXI Annual Return On Equity	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	4	32	84	0	0
Y / Y Equity Change	-89.13 %	-61.44 %	-	-	-
Net Income in Millions	-32	-63	-51	0	0
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-921.57 %	-193.51 %	-60.77 %	-	-

Back to NEXI Management Effectiveness >> NEXI's 5 Years Annual ROE >> Compare NEXI ROE to its Competitors

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NEXI's' Return on Equity at Yahoo Finance
NEXI's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NEXI's Competitors
Subscribers only: Roe for Neximmune Inc 's Suppliers
Subscribers only: Return On Equity for NEXI's Customers

Companies with similar Return On Equity at Jun 30 2024, within Healthcare Sector

ROE

Date modified: 2026-09-26T07:39:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.